128例侵袭性肺曲霉病临床疗效分析

中国真菌学杂志　 2014, Vol. 9 　Issue (3): 159-162,169.

128例侵袭性肺曲霉病临床疗效分析

冯秀娟^1,2, 叶慧¹, 钟册俊¹, 刘真真¹, 吕晓菊¹

1. 四川大学华西医院感染性疾病中心, 成都 610041;
2. 电子科技大学医院, 成都 611371

收稿日期:2014-01-23 出版日期:2014-06-28 发布日期:2014-06-28
通讯作者: 吕晓菊，E-mail：lvxj3369@163.com E-mail:lvxj3369@163.com
作者简介:冯秀娟，女（汉族），硕士研究生在读.E-mail：xiujuanf@gmail.com.cn

The treatment of 128 patients with invasive pulmonary aspergillosis

FENG Xiu-juan^1,2, YE Hui¹, ZHONG Ce-jun¹, LIU Zhen-zhen¹, LV Xiao-ju¹

1. Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041;
2. The Hospital Attached to University of Electronic Science and Technology of China, Chengdu 611371

Received:2014-01-23 Online:2014-06-28 Published:2014-06-28

摘要/Abstract

摘要：

目的通过回顾性病例分析，加强对侵袭性肺曲霉病的认识，重视对侵袭性肺曲霉病的分级诊断，从而制定合理治疗方案。方法对四川大学华西医院2011年1~12月128例诊断为侵袭性肺曲霉病患者的临床资料进行回顾性分析，重点分析基础疾病、临床表现、影像学表现、诊断及治疗方法。结果确诊17例；依据宿主危险因素、临床表现及反复痰培养阳性拟诊111例。128例患者均伴有基础疾病。治疗方案包括伏立康唑（86例），两性霉素B脂质体（1例），伊曲康唑（12例），米卡芬净（3例），卡泊芬净（3例），两性霉素B去氧胆酸盐（10例），伏立康唑联合米卡芬净（1例）。治愈或好转81例（63.28%），自动出院24例（18.75%），死亡23例（17.97%）。结论侵袭性肺曲霉病患者多数伴有多种感染危险因素，应当重视侵袭性肺曲霉病的分级诊断，据不同情况给予适当抗真菌治疗，以降低患者病死率。

关键词: 侵袭性肺曲霉病, 分层诊断, 治疗

Abstract:

Objective To improve understanding of invasive pulmonary asperginosis (IPA) and pay more attention to the classification of IPA so as to provide evidences for rational antifungal chemotherapy.Method The clinical features of 128 cases of IPA were analyzed retrospectively in West China Hospital of Sichuan University from January to December in 2011. This study focused on the risk factors, clinical manifestations, imaging findings, diagnosis and treatment methods. A total of 128 patients were enrolled.Results Seventeen patients were confirmed IPA by the positive culture results from the specimens collected by the bronchoscopy. One hundred and eleven patients were diagnosed as probable IPA. All patients had underlying diseases. All patients accepted antifungal treatment. The antifungal agents included voriconazole (86), amphotericin B liposome (1), itraconazole (12),micafindan (3), capofungin (15),amphotericin B (10) and voriconazole combined with caspofungin (1). Eighty-one patients (63.28%) were cured or improved. Twenty-four patients (18.75%) discharged from hospital due to poor economic conditions. Twenty-three patients (17.97%) died.Conclusion Most IPA patients had a variety of risk factors for infection. To reduce mortality rate of IPA, we should pay more attention to its stratification diagnosis, and choose appropriate antifungal agents.

Key words: invasive pulmonary aspergillosis, stratification diagnosis, treatment

中图分类号:

R563

冯秀娟, 叶慧, 钟册俊, 刘真真, 吕晓菊. 128例侵袭性肺曲霉病临床疗效分析[J]. 中国真菌学杂志, 2014, 9(3): 159-162,169.

FENG Xiu-juan, YE Hui, ZHONG Ce-jun, LIU Zhen-zhen, LV Xiao-ju. The treatment of 128 patients with invasive pulmonary aspergillosis[J]. Chinese Journal of Mycology, 2014, 9(3): 159-162,169.

参考文献

[1] Xu XY, Sun HM, Zhao BL, et al. Diagnosis of airway-invasive pulmonary aspergillosis by tree-in-bud sign in an immunocompetent patient: case report and literature review
[J]. J Mycol Med,2013,23(1):64-69.

[2] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical Practice Guidelines of the Infections diseases society of America
[J]. Clin Infect Dis,2008,46(3):327-360.

[3] 唐晓丹,李光辉.曲霉病的治疗:美国感染病学会临床实用指南
[J].中国感染与化疗杂志,2008,8(3):161-166.

[4] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
[J]. Clin Infect Dis,2008,46(12):1813-1821.

[5] Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen
[J]. Clin Microbiol Infect, 2005,11(6):427-429.

[6] Guinea J, Torres-Narbona M, Gijon P,et al.Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors,and outcome
[J]. Clin Microbiol Infect,2010,16(7):870-877.

[7] Valerior A, Fabiano N, Huander FA, et al. The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD)
[J]. Mycopathologia,2012,174(2):163-169.

[8] Samarakoon P, Soubani AO. Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature
[J]. Chron Respir Dis, 2008, 5(1): 19-27.

[9] Marya D. Zilberberg, Andrew F. Shorr. Fungal infections in the ICU
[J]. Infect Dis Clin N Am, 2009, 23(3): 625-642.

[10] Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign
[J]. Clin Infect Dis, 2007,44(3):373-379.

[11] 朱小敏, 周新. 侵袭性肺曲霉病的诊断与治疗
[J]. 中国呼吸与危重监护杂志, 2005, 4(4):316-320.

[12] Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients
[J]. Bone Marrow Transplant,2009,44(6): 361-370.

[13] Pasqualotto AC. Aspergillosis: from diagnosis to prevention
[M].Germany: springer, 2010:437-448.

[1]	中国手癣和足癣诊疗指南工作组. 中国手癣和足癣诊疗指南(基层实践版2020)[J]. 中国真菌学杂志, 2020, 15(6): 325-330.
[2]	季梅, 隗祎. 儿童脓癣2例[J]. 中国真菌学杂志, 2020, 15(6): 366-367,377.
[3]	特比萘芬临床应用专家共识工作组. 特比萘芬临床应用专家共识[J]. 中国真菌学杂志, 2020, 15(5): 257-261.
[4]	王玲, 景东云, 王学军, 刘俊, 曹月清. 长脉宽Nd:YAG 1064 nm激光治疗远端侧位甲下型甲真菌病的疗效观察及对真菌超微结构的影响[J]. 中国真菌学杂志, 2020, 15(5): 268-273.
[5]	李敬波, 徐宇, 张芙蓉. Majocchi肉芽肿研究进展[J]. 中国真菌学杂志, 2020, 15(5): 306-309.
[6]	步青云, 王润超, 罗亭, 卢昌佩, 景海霞. 甲真菌病的激光治疗新进展[J]. 中国真菌学杂志, 2020, 15(5): 310-313.
[7]	梁官钊, 刘维达. 球孢子菌病的临床特征及诊治策略[J]. 中国真菌学杂志, 2020, 15(5): 314-317.
[8]	余进, 刘伟, 陈伟, 张晓梅, 万喆, 王爱平, 李若瑜. 关于重症新型冠状病毒肺炎继发侵袭性真菌感染实验室诊治建议[J]. 中国真菌学杂志, 2020, 15(1): 1-5.
[9]	蔡开霞, 周晶, 曹薇, 王胜昱. 支气管肺泡灌洗液半乳甘露聚糖检测对侵袭性肺曲霉病诊断价值的meta分析[J]. 中国真菌学杂志, 2019, 14(5): 284-291.
[10]	朱红梅, 温海, 李斌. 外用抗真菌中草药的研究进展[J]. 中国真菌学杂志, 2019, 14(5): 316-320.
[11]	孙祺琳, 王桂祯, 陈骏, 刘洋, 杨雅骊, 徐慧. 马拉色菌引起乳房垢着病1例并文献分析[J]. 中国真菌学杂志, 2019, 14(3): 164-168.
[12]	沈煜宸, 曹毅, 陶茂灿. 白念珠菌生物膜耐药机制及中药治疗的研究进展[J]. 中国真菌学杂志, 2019, 14(3): 176-179.
[13]	杨之辉, 余进, 李若瑜. 中国大陆地区赛多孢霉感染流行现状的回顾性分析[J]. 中国真菌学杂志, 2019, 14(3): 183-188,192.
[14]	中国体癣和股癣诊疗指南工作组. 中国体癣和股癣诊疗指南(2018修订版)[J]. 中国真菌学杂志, 2019, 14(1): 1-3.
[15]	中国头癣诊疗指南工作组. 中国头癣诊断和治疗指南(2018修订版)[J]. 中国真菌学杂志, 2019, 14(1): 4-6.